Competitor Analysis: Antithrombotics Provides a Competitor Evaluation in the Field of Anticoagulants and Antiplatelet Agents
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/research/669111/competitor_analysi) has announced the addition of the “Competitor Analysis: Antithrombotics” report to their offering.
The Competitive Intelligence Report Antithrombotics as of May 2007 provides a competitor analysis in the development pipeline of novel anticoagulant and antiplatelet agents directed against targets such as factor IIa (thrombin), factor Xa, the ADP platelet receptor and PAR-1 /thrombin receptor and other novel targets.
Anticoagulants Oral Thrombin Inhibitors, F. Xa inhibitors, dual thrombin and factor Xa inhibitors are among the most advanced novel anticoagulants. Anticoagulants are used for treatment and prevention of deep venous thrombosis and pulmonary embolism and especially for prophylaxis of venous thromboembolism after surgery such as hip and knee replacement.
Antiplatelet agents Antiplatelet agents are used for treatment and prevention of arterial thrombosis in diseases such as acute coronary syndrome and prevention of stroke in patients with atrial. Among the important targets are the inhibitors of the platelet P2(Y12) ADP receptor and the thrombin receptor / PAR-1 (protease-activated receptor-1). New directions of research and development are directed at providing novel orally available oral anticoagulants and antiplatelet agents with improved efficacy and less bleeding side effects. Major players in antithrombosis R&D are Sanofi-Aventis, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Pfizer, Bayer Schering Pharma, Organon Biosciences & Schering-Plough, GlaxoSmithKline, Daiichi-Sankyo & Eli Lilly, and Astellas Pharma apart from many other companies with innovative projects.
The present Competitive Intelligence Report of Antithrombotics provides a competitor evaluation in the field of anticoagulants and antiplatelet agents used to treat and prevent thrombotic disorders as of May 2007. The report includes a compilation of current leading antithrombotic therapies including 2006 sales figures of the leading products and new projects in research and development. Competitor projects are listed on 20 pages in a tabular format providing Information on:
Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information.
The Competitive Intelligence Report Antithrombotics as of May 2007 provides a competitor analysis in the development pipeline of novel anticoagulant and antiplatelet agents directed against targets such as factor IIa (thrombin), factor Xa, the ADP platelet receptor and PAR-1 / thrombin receptor and other novel targets
Key Topics Covered:
Anticoagulants Anti-thrombin III Agonists: Heparin, Low Molecular Weight Heparin, ATIII Inhibitors of Factor IIa (Thrombin) Inhibitors of Factor Xa Dual Inhibitors of Factor IIa and Xa Inhibitors of Factor IXa Inhbitors of Factor VII/Tissue Factor Inhibitors of Factor VIII Antiplatelet Agents Inhibitors of Platelet ADP Receptor Inhibitors of PAR-1 / Thrombin Receptor Antagonists of GPIIb/IIIa Antagonists of GPIb & von Willebrand Factor Antagonists of GPVI Antithrombotics
Novel Targets Various & Not Specified Terminated Projects & No Develoment Reported
For more information visit http://www.researchandmarkets.com/research/669111/competitor_analysi
COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning